Maximum Recommended Daily Dose of Gliclazide
The maximum recommended daily dose is 320 mg for gliclazide immediate-release (IR) and 120 mg for gliclazide modified-release (MR) formulations 1.
Dosing by Formulation
Immediate-Release (IR) Formulation
- Starting dose: 5 mg before breakfast (2.5 mg in elderly or those with liver disease)
- Maximum single dose: 15 mg once daily
- Maximum total daily dose: 40 mg, though 320 mg has been safely administered in divided doses (typically twice daily) to long-term patients 1
- Doses above 15 mg should be divided and given before meals
- Doses above 30 mg are typically given twice daily 1
Modified-Release (MR) Formulation
- Starting dose: 30 mg once daily
- Maximum dose: 120 mg once daily 2, 3
- The MR formulation uses a hydrophilic matrix polymer that provides progressive 24-hour drug release, allowing once-daily dosing 2
- In clinical practice, 60 mg is the most commonly prescribed MR dose (62.5% of prescriptions) 4
Key Clinical Considerations
The FDA-approved maximum of 40 mg for IR formulation appears conservative compared to actual clinical practice, where 320 mg daily in divided doses has been safely used 1. However, recent pharmacometric modeling suggests the recommended IR dose of 320 mg is appropriate with no additional efficacy gained at higher doses 5.
For the MR formulation, while 120 mg is the current maximum, modeling studies suggest the dose could potentially be increased to 270 mg to achieve better HbA1c goals without exceeding the hypoglycemia risk of the IR formulation 5. However, this remains investigational and the current approved maximum remains 120 mg daily.
Practical Dosing Guidance
- IR formulation: Titrate in 2.5-5 mg increments with several days between adjustments 1
- MR formulation: The breakable 60 mg tablet allows simple two-step titration (60 mg → 90 mg → 120 mg) 6
- Both formulations demonstrate similar efficacy when dosed appropriately, with MR showing approximately 50% fewer confirmed hypoglycemic episodes compared to other sulfonylureas 7
Special Populations
In elderly, debilitated, malnourished patients, or those with renal/hepatic impairment, use conservative initial and maintenance dosing to avoid hypoglycemia 1. The MR formulation is particularly suitable for elderly patients due to its low hypoglycemia risk and lack of active metabolites 8.